Allogene Therapeutics, Inc. - Common Stock (ALLO)

Historical Holders from Q1 2016 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: ALLO on Nasdaq
Shares outstanding: 226,220,429
Price per share: $1.24
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 162,111,006
Total reported value: $201,030,848
% of total 13F portfolios: 0%
Share change: -21,505,832
Value change: -$24,340,243
Number of holders: 167
Price from insider filings: $1.37

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Allogene Therapeutics, Inc. - Common Stock (ALLO) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
CITADEL ADVISORS LLC	6.1%		$15,081,151		13,346,151		Kenneth Griffin	09 Jul 2025
Belldegrun Arie	5.6%	-1.7%	$15,708,747	+$77,438	12,668,344	+0.5%	Arie Belldegrun, M.D.	30 Sep 2025
BlackRock, Inc.	5.3%		$15,686,608		11,450,079		BlackRock, Inc.	31 Mar 2025
Chang David D	4.9%	-2%	$13,931,298	+$121,756	11,234,918	+0.88%	David D. Chang, M.D., Ph.D.	30 Sep 2025
Lynx1 Capital Management LP	5.2%		$14,898,371		10,874,723		Lynx1 Capital Management LP	31 Dec 2024
FMR LLC	4.9%	-58%	$14,009,416	-$18,558,217	10,225,851	-57%	FMR LLC	28 Feb 2025

As of 30 Sep 2025, Allogene Therapeutics, Inc. - Common Stock (ALLO) has 167 institutional shareholders filing 13F forms. They hold 162,111,006 shares. of 226,220,429 outstanding shares (72%) .

Top 25 institutional shareholders own 62% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
Pfizer Inc	9.7%	22,032,040	0%	6.2%	$27,319,730
TPG GP A, LLC	8.3%	18,716,306	0%	1.3%	$23,208,219
BlackRock, Inc.	7.7%	17,514,674	-2.1%	0%	$21,718,195
CITADEL ADVISORS LLC	6.2%	13,971,557	+36%	0.01%	$17,324,731
VANGUARD GROUP INC	4%	9,020,770	+9.2%	0%	$11,185,755
PRIMECAP MANAGEMENT CO/CA/	3.1%	7,079,308	+24%	0.01%	$8,778,342
Woodline Partners LP	1.9%	4,360,608	0%	0.03%	$5,407,154
Frazier Life Sciences Management, L.P.	1.7%	3,868,750	0%	0.14%	$4,797,250
GEODE CAPITAL MANAGEMENT, LLC	1.7%	3,833,885	+1%	0%	$4,754,796
PRICE T ROWE ASSOCIATES INC /MD/	1.6%	3,677,474	-8.8%	0%	$4,561,000
UBS Group AG	1.6%	3,571,157	+75%	0%	$4,428,235
MILLENNIUM MANAGEMENT LLC	1.5%	3,390,026	+126%	0%	$4,203,632
TWO SIGMA INVESTMENTS, LP	1.5%	3,383,644	+110%	0.01%	$4,195,719
Patient Square Capital LP	1.3%	2,981,396	+13%	0.99%	$3,696,931
Wildcat Capital Management, LLC	1.3%	2,920,787	0%	2.5%	$3,621,776
RENAISSANCE TECHNOLOGIES LLC	1.3%	2,893,812	+73%	0%	$3,588,327
TWO SIGMA ADVISERS, LP	1.2%	2,781,600	+57%	0.01%	$3,449,184
STATE STREET CORP	1.2%	2,755,378	+1.2%	0%	$3,416,669
DIMENSIONAL FUND ADVISORS LP	0.92%	2,090,753	-24%	0%	$2,592,869
AQR CAPITAL MANAGEMENT LLC	0.82%	1,853,554	+2199%	0%	$2,298,407
Vida Ventures Advisors, LLC	0.79%	1,798,163	0%	7.6%	$2,229,722
Aberdeen Group plc	0.7%	1,582,265	+82%	0%	$1,962,009
DAFNA Capital Management LLC	0.61%	1,380,118	0%	0.42%	$1,711,346
MORGAN STANLEY	0.57%	1,299,166	+113%	0%	$1,610,966
NORTHERN TRUST CORP	0.57%	1,279,628	+0.42%	0%	$1,586,739

Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	92,930	$129,703	+$30,469			$1.37	4
2025 Q3	162,111,006	$201,030,848	-$24,340,243	$44,888	$94,984	$1.24	167
2025 Q2	183,617,715	$207,883,296	-$15,409,901	$109,723	$165,093	$1.13	154
2025 Q1	196,986,783	$288,577,409	+$11,151,082	$111,836	$295,504	$1.46	167
2024 Q4	188,404,830	$401,310,730	-$12,951,875	$112,464	$161,454	$2.13	169
2024 Q3	164,371,652	$460,365,153	-$1,960,306	$317,520	$166,320	$2.80	152
2024 Q2	165,199,031	$384,926,165	+$75,173,711	$260,028	$219,719	$2.33	168
2024 Q1	131,205,694	$586,005,669	+$41,663,072	$203,832	$435,825	$4.47	158
2023 Q4	769,747	$2,472,772	-$677,258			$3.21	3
2023 Q3	128,787,064	$408,249,249	-$15,675,875	$132,189	$18,703	$3.17	149
2023 Q2	131,603,897	$653,917,240	+$73,825,404	$167,489	$91,945	$4.97	165
2023 Q1	115,525,619	$570,761,427	+$24,488,348	$1,185,106	$244,036	$4.94	170
2022 Q4	110,969,165	$697,661,522	+$17,094,998	$393,125	$227,069	$6.29	160
2022 Q3	102,004,067	$1,101,036,604	+$60,201,207	$774,000	$872,000	$10.80	175
2022 Q2	95,102,415	$1,084,114,613	+$106,595,298	$119,000	$694,000	$11.40	150
2022 Q1	91,656,720	$835,579,228	+$16,210,908	$701,000	$1,066,000	$9.11	172
2021 Q4	84,441,610	$1,260,117,619	-$107,692,749	$1,206,000	$1,951,000	$14.92	164
2021 Q3	86,131,474	$2,213,651,062	+$36,043,218	$3,953,000	$2,044,000	$25.70	164
2021 Q2	86,300,061	$2,250,274,646	-$84,501,881	$4,399,000	$4,424,000	$26.08	178
2021 Q1	86,534,861	$3,054,470,350	-$11,359,921	$4,490,000	$15,277,000	$35.30	166
2020 Q4	86,788,183	$2,190,645,206	+$104,550,405	$3,195,000	$2,688,000	$25.24	155
2020 Q3	82,336,350	$3,104,893,381	-$164,166,264	$5,290,000	$5,461,000	$37.71	155
2020 Q2	86,223,636	$3,691,724,138	+$661,660,811	$7,543,000	$13,768,000	$42.82	167
2020 Q1	73,319,077	$1,426,826,188	+$28,190,602	$1,841,000	$1,668,000	$19.44	112
2019 Q4	71,621,056	$1,860,738,066	+$104,849,838	$2,139,000	$2,313,000	$25.98	113
2019 Q3	64,587,234	$1,760,321,211	+$43,617,370	$2,176,000	$10,475,000	$27.26	92
2019 Q2	62,997,933	$1,691,474,303	+$161,175,863	$1,461,000	$1,984,000	$26.85	93
2019 Q1	57,709,522	$1,661,351,410	+$80,500,340	$2,266,000	$2,296,000	$28.91	86
2018 Q4	54,998,315	$1,469,849,010	+$1,469,848,998		$902,000	$26.93	79
2016 Q1	4,033	$115,000	$0			$28.51	1